Back to top

Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Oncternal Therapeutics (ONCT – Research Report) today. The company’s shares closed yes...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Oncternal Therapeutics, Inc. (ONCT)